Coronary Heart Disease Clinical Trials

Find Coronary Heart Disease Clinical Trials Near You

Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients who meet ALL inclusion criteria will be included:

• Patients aged ≥ 18 years AND;

• Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;

• Patients with at least one lesion fulfilling the long lesion criteria suitable for a single stent approach AND;

• Patients who have been informed of the characteristics of the study and have provided written informed consent AND;

• Intention to treat all lesions with the Ultimaster Nagomi™ stent

Locations
Other Locations
Spain
Hospital Universitario de Cabueñes
RECRUITING
Cabueñes
Hospital General Universitario de Elche
RECRUITING
Elche
Hospital Universitario de Leon
RECRUITING
León
Hospital Universitario Regional de Málaga
RECRUITING
Málaga
Hospital Universitario de Navarra
RECRUITING
Pamplona
Hospital Universitario Marqués de Valdecilla
RECRUITING
Santander
Contact Information
Primary
TAMARA GARCIA CAMARERO, MD, PhD
tgcamarero@gmail.com
0034615420460
Backup
FUNDACION EPIC
iepic@fundacionepic.org
00987876135
Time Frame
Start Date: 2026-02-27
Estimated Completion Date: 2029-01-01
Participants
Target number of participants: 1039
Treatments
Coronary Artery Disease (CAD)
Related Therapeutic Areas
Sponsors
Leads: Fundación EPIC

This content was sourced from clinicaltrials.gov